Insulet Co. (NASDAQ:PODD) Shares Sold by AtonRa Partners

AtonRa Partners trimmed its stake in shares of Insulet Co. (NASDAQ:PODD) by 7.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,434 shares of the medical instruments supplier’s stock after selling 278 shares during the period. Insulet accounts for 1.5% of AtonRa Partners’ holdings, making the stock its 12th biggest position. AtonRa Partners’ holdings in Insulet were worth $745,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of PODD. Consolidated Portfolio Review Corp lifted its stake in Insulet by 1.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock valued at $806,000 after buying an additional 57 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its stake in shares of Insulet by 1.3% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock worth $1,262,000 after acquiring an additional 73 shares during the last quarter. Lindbrook Capital LLC boosted its stake in shares of Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after acquiring an additional 75 shares during the last quarter. New York Life Investment Management LLC increased its position in shares of Insulet by 0.8% during the third quarter. New York Life Investment Management LLC now owns 10,035 shares of the medical instruments supplier’s stock worth $1,600,000 after purchasing an additional 82 shares in the last quarter. Finally, Avior Wealth Management LLC raised its stake in Insulet by 3.6% in the 4th quarter. Avior Wealth Management LLC now owns 2,645 shares of the medical instruments supplier’s stock valued at $574,000 after purchasing an additional 91 shares during the last quarter.

Insider Activity at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.47% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Stifel Nicolaus increased their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Piper Sandler dropped their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Finally, Barclays reduced their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

Insulet Trading Up 2.4 %

Shares of PODD stock traded up $4.07 during trading hours on Monday, hitting $170.26. The company had a trading volume of 602,109 shares, compared to its average volume of 859,181. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The company’s fifty day moving average is $171.09 and its 200 day moving average is $180.25. The stock has a market capitalization of $11.92 billion, a PE ratio of 58.51, a price-to-earnings-growth ratio of 2.99 and a beta of 0.98.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The company had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same period in the prior year, the firm earned $0.55 earnings per share. The firm’s revenue was up 37.9% compared to the same quarter last year. Research analysts expect that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.